View Filing Data

Segment Information (Tables)

3 Months Ended

Dec. 31, 2019

Segment Revenue, Operating (Loss) Income and Depreciation and Amortization

Segment revenue, operating (loss) income, and depreciation and amortization, were as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2019			2018
Revenue:
Medical Device	$	17,404		$	17,258
In Vitro Diagnostics		5,212			4,983
Total revenue	$	22,616		$	22,241

Operating (loss) income:
Medical Device	$	(423	)	$	357
In Vitro Diagnostics		2,599			2,455
Total segment operating income		2,176			2,812
Corporate		(2,442	)		(2,100	)
Total operating (loss) income	$	(266	)	$	712

Depreciation and amortization:
Medical Device	$	1,455		$	1,388
In Vitro Diagnostics		110			116
Corporate		239			252
Total depreciation and amortization	$	1,804		$	1,756

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Current Assets:
Cash and cash equivalents	$ 9,006	$ 30,361
Available-for-sale securities	39,256	24,931
Accounts receivable, net of allowance for doubtful accounts of $176 and $200 as of December 31, 2019 and September 30, 2019, respectively	7,681	8,993
Contract assets - royalties and license fees	7,847	8,210
Inventories, net	4,951	4,501
Income tax receivable	561	558
Prepaids and other	4,164	3,866
Total Current Assets	73,466	81,420
Property and equipment, net	30,766	29,748
Deferred income taxes	6,370	6,176
Intangible assets, net	13,785	14,226
Goodwill	26,546	26,171
Other assets	4,125	2,124
Total Assets	155,058	159,865
Current Liabilities:
Accounts payable	2,396	2,085
Accrued liabilities:
Compensation	1,989	4,581
Accrued other	4,878	4,790
Deferred revenue	4,928	5,553
Contingent consideration		3,200
Total Current Liabilities	14,191	20,209
Deferred revenue, less current portion	10,907	11,628
Other long-term liabilities	6,634	5,512
Total Liabilities	31,732	37,349
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Series A Preferred stock — $.05 par value, 450,000 shares authorized; no shares issued and outstanding
Common stock — $.05 par value, 45,000,000 shares authorized; 13,593,069 and 13,504,102 shares issued and outstanding as of December 31, 2019 and September 30, 2019, respectively	680	675
Additional paid-in capital	10,361	10,740
Accumulated other comprehensive income	1,432	396
Retained earnings	110,853	110,705
Total Stockholders’ Equity	123,326	122,516
Total Liabilities and Stockholders’ Equity	$ 155,058	$ 159,865

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 148	$ 1,310
Other comprehensive income (loss):
Unrealized holding gains on available-for-sale securities, net of tax	(5)	4
Foreign currency translation adjustments	1,041	(538)
Other comprehensive income (loss)	1,036	(534)
Comprehensive income	$ 1,184	$ 776

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	$ 26,546	$ 26,171

Basis of Presentation

3 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation

1. Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.”) (“GAAP”) and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, needed to fairly present the financial results of Surmodics, Inc. and subsidiaries (“Surmodics” or the “Company”) for the periods presented. These financial statements include amounts that are based on management’s best estimates and judgments. These estimates may be adjusted as more information becomes available, and any adjustment could be significant. The impact of any change in estimates is included in the determination of net income (loss) in the period in which the change in estimate is identified. The results of operations for the three months ended December 31, 2019 are not necessarily indicative of the results that may be expected for the entire 2020 fiscal year.

In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2019, and footnotes thereto included in the Company’s Annual Report on Form 10-K as filed with the SEC on December 3, 2019.

New Accounting Pronouncements

Recently Adopted

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2016-02, Leases (“ASC Topic 842”). The update maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees recognize a right-of-use asset and a lease liability on the consolidated balance sheets for those leases previously classified as operating leases under the previous guidance. The liability is equal to the present value of lease payments, while the asset is based on the liability, subject to adjustment, such as for direct costs.

Effective October 1, 2019, the Company adopted the new lease accounting standard using the optional transition method which allowed us to continue to apply the guidance under the lease standard in effect at the time in the comparative periods presented. In addition, the Company elected the package of practical expedients, including opting not to reassess whether any existing contracts contain a lease, historical lease classification as operating or finance leases, or initial direct costs. The Company has also elected the practical expedient to not separate the lease and non-lease components for all classes of underlying assets. The Company elected the short-term lease recognition exemption for all leases that qualified and has accordingly excluded short-term leases from the recognition of right-of-use assets and lease liabilities.

As a result of adoption of Accounting Standards Codification (“ASC”) Topic 842, we recorded operating lease right-of-use assets and corresponding operating lease liabilities of approximately $1.7 million and $2.9 million, respectively, as of October 1, 2019 with no impact on retained earnings. In addition, deferred rent liabilities related to escalating rent payments and tenant incentives totaling approximately $1.2 million were eliminated upon adoption, as these items are netted against right-of-use assets. The condensed consolidated balance sheets for reporting periods beginning on or after October 1, 2019 are presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previous guidance.

Not Yet Adopted

In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses, Measurement of Credit Losses on Financial Statements. This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2021 (October 1, 2020). Early adoption is permitted and the guidance will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0.7	$ 0.7

Intangible Assets

3 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets

8. Intangible Assets

Intangible assets consist principally of acquired patents and technology, customer lists and relationships, licenses and trademarks. The Company recorded amortization expense of $0.7 million for both the three months ended December 31, 2019 and 2018.

Intangible assets consisted of the following:

	December 31, 2019
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,684	$	(11,177	)	$	6,507
Developed technology		11.5	$	9,562	$	(3,453	)	$	6,109
Non-compete		5.0	$	230	$	(207	)	$	23
Patents and other		16.5	$	2,321	$	(1,755	)	$	566
Subtotal				29,797		(16,592	)		13,205
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total			$	30,377	$	(16,592	)	$	13,785

	September 30, 2019
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,374	$	(10,661	)	$	6,713
Developed technology		11.5		9,490		(3,196	)		6,294
Non-compete		5.0		230		(196	)		34
Patents and other		16.5		2,321		(1,716	)		605
Subtotal				29,415		(15,769	)		13,646
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total			$	29,995	$	(15,769	)	$	14,226

Based on the intangible assets in service as of December 31, 2019, estimated amortization expense for the remainder of fiscal 2020 and each of the next five fiscal years is as follows (in thousands):

Remainder of 2020	$	1,799
2021		2,319
2022		2,279
2023		1,668
2024		1,610
2025		1,553

Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, changes in amortization periods, foreign currency translation rates, or other factors.

Leases - Schedule of Operating Lease Maturities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Oct. 01, 2019
Operating Lease Liabilities Payments Due [Abstract]
Remainder of 2020	$ 376
2021	538
2022	536
2023	547
2024	558
2025	570
Thereafter	1,965
Total expected operating lease payments	5,090
Less: Imputed interest	(2,224)
Total operating lease liabilities	$ 2,866	$ 2,900

Goodwill - Schedule of Carrying Amount of Goodwill by Segment (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2019 USD ($)
Goodwill [Line Items]
Balance as of September 30, 2019	$ 26,171
Currency translation adjustment	375
Balance as of December 31, 2019	26,546
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Balance as of September 30, 2019	8,010
Balance as of December 31, 2019	8,010
Medical Device [Member]
Goodwill [Line Items]
Balance as of September 30, 2019	18,161
Currency translation adjustment	375
Balance as of December 31, 2019	$ 18,536

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Dec. 31, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2016-02, Leases (“ASC Topic 842”). The update maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees recognize a right-of-use asset and a lease liability on the consolidated balance sheets for those leases previously classified as operating leases under the previous guidance. The liability is equal to the present value of lease payments, while the asset is based on the liability, subject to adjustment, such as for direct costs. Effective October 1, 2019, the Company adopted the new lease accounting standard using the optional transition method which allowed us to continue to apply the guidance under the lease standard in effect at the time in the comparative periods presented. In addition, the Company elected the package of practical expedients, including opting not to reassess whether any existing contracts contain a lease, historical lease classification as operating or finance leases, or initial direct costs. The Company has also elected the practical expedient to not separate the lease and non-lease components for all classes of underlying assets. The Company elected the short-term lease recognition exemption for all leases that qualified and has accordingly excluded short-term leases from the recognition of right-of-use assets and lease liabilities. As a result of adoption of Accounting Standards Codification (“ASC”) Topic 842, we recorded operating lease right-of-use assets and corresponding operating lease liabilities of approximately $1.7 million and $2.9 million, respectively, as of October 1, 2019 with no impact on retained earnings. In addition, deferred rent liabilities related to escalating rent payments and tenant incentives totaling approximately $1.2 million were eliminated upon adoption, as these items are netted against right-of-use assets. The condensed consolidated balance sheets for reporting periods beginning on or after October 1, 2019 are presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previous guidance. Not Yet Adopted In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses, Measurement of Credit Losses on Financial Statements. This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2021 (October 1, 2020). Early adoption is permitted and the guidance will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.
Leases	The Company leases facilities for research, office, manufacturing and warehousing. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability based on the net present value of the future minimum lease payments over the lease term at the commencement date. The unamortized balance of leasehold improvement incentives in the form of tenant allowances represents the primary difference between the balance of the right-of-use assets and operating lease liabilities. As the Company’s leases typically do not provide an implicit rate, the Company’s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. The condensed consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the condensed consolidated statements of income on a straight-line basis over the lease term. The Company’s leases include one or more options to renew and extend the lease term at the Company’s discretion. These renewal options are not included in our right-of-use assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal period in our lease term.

Investments - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 39,251	$ 24,918
Unrealized Gains	5	13
Fair Value	39,256	24,931
Commercial paper and corporate bonds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	39,251	24,918
Unrealized Gains	5	13
Fair Value	$ 39,256	$ 24,931

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	3 Months Ended		12 Months Ended	60 Months Ended
	Jul. 31, 2019 USD ($)	Dec. 31, 2019 USD ($) € / $	Dec. 31, 2019 EUR (€)	Sep. 30, 2018 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2019 USD ($)
Commitments And Contingencies [Line Items]
Exchange rate relating to license payment \| € / $		1.1215
Other long-term liabilities		$ 6,634,000				$ 5,512,000
Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Contingent payments upon achievement of regulatory milestones		$ 2,000,000
Installment payment beginning period		2020	2020
Installment payment ending period		2024	2024
CRO [Member]
Commitments And Contingencies [Line Items]
Contractual obligation to be paid		$ 11,900,000
CRO [Member] \| Maximum [Member]
Commitments And Contingencies [Line Items]
Contractual obligations		26,000,000
Contractual obligation due in next several years		40,000,000
CRO [Member] \| Minimum [Member]
Commitments And Contingencies [Line Items]
Contractual obligation due in next several years		$ 35,000,000
License [Member]
Commitments And Contingencies [Line Items]
License agreement commencement date		2006-03	2006-03
Annual minimum payments for licenses		$ 224,000	€ 200,000
Future minimum payments associated with license		$ 1,800,000
Patents [Member]
Commitments And Contingencies [Line Items]
Patent expiry date		2027-09	2027-09
Intellectual Property [Member] \| Medical Device [Member]
Commitments And Contingencies [Line Items]
Payments to acquire intellectual property assets	$ 800,000
Contingent payments upon achievement of regulatory milestones	$ 1,300,000
Contingency period ending year	2022
Estimated additional payment to acquire intellectual property assets	$ 200,000
Intellectual Property [Member] \| Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Payments to acquire intellectual property assets				$ 5,000,000
Contingency period ending year		2033	2033
Other accrued liabilities noncurrent		$ 1,200,000				1,000,000
Other long-term liabilities		$ 2,100,000				$ 2,100,000
Intellectual Property [Member] \| Embolitech LLC [Member] \| Scenario Forecast [Member]
Commitments And Contingencies [Line Items]
Estimated additional payment to acquire intellectual property assets					$ 3,500,000

Commitments and Contingencies

3 Months Ended

Dec. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

16. Commitments and Contingencies

Litigation. From time to time, the Company may become involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which if granted, could require significant expenditures or result in lost revenue. The Company records a liability in the condensed consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded.

InnoCore Technologies BV. In March 2006, the Company entered into a license agreement whereby the Company obtained an exclusive license to a drug delivery coating for licensed products within the vascular field which included peripheral, coronary and neurovascular biodurable stent products. The license requires an annual minimum payment of 200,000 euros (equivalent to $224,000 using a euro to US dollar exchange rate of $1.1215 to the Euro as of December 31, 2019) until the last patent expires, which is currently estimated to be September 2027. The total minimum future payments associated with this license are approximately $1.8 million as of December 31, 2019. The license is currently utilized by one of the Company’s drug delivery customers.

Clinical Trials. The Company has engaged clinical trial clinical research organization (“CRO”) consultants to assist with the administration of its ongoing clinical trials. The Company has executed separate contracts with two CROs for services rendered in connection with the TRANSCEND pivotal clinical trial for the SurVeil DCB, including pass-through expenses paid by the CROs, of up to $26 million in the aggregate. As of December 31, 2019, an estimated $11.9 million remains to be paid on these contracts, which may vary depending on actual pass-through expenses incurred to execute the trial. The Company estimates that the total cost of the TRANSCEND clinical trial will be in the range of $35 million to $40 million from inception to completion. In the event the Company were to terminate any trial, it may incur certain financial penalties which would become payable to the CRO for costs to wind down the terminated trial.

Asset Acquisitions. In July 2019, the Company acquired certain intellectual property assets supporting ongoing development of the Company’s medical device pipeline. As a result of this acquisition, the Company made an upfront, nonrefundable payment of $0.8 million. In addition, the Company is obligated to pay up to $1.3 million of additional consideration upon achievement of certain strategic milestones within a contingency period ending in 2022, of which $0.2 million is guaranteed to be paid in fiscal 2021.

In May 2018, the Company acquired certain intellectual property assets of Embolitech, LLC (the “Embolitech Transaction”). As part of the Embolitech Transaction, the Company paid the sellers $5.0 million during fiscal 2018. Additionally, the Company is obligated to pay $3.5 million in several installments beginning in fiscal 2020 and ending in fiscal 2024. These payments may be accelerated upon the occurrence of certain sales and regulatory milestones. An additional $2.0 million payment is contingent upon the achievement of certain regulatory milestones within a contingency period ending in 2033.

As of December 31, 2019, $1.2 million and $2.1 million, respectively, is included in other accrued and other long-term liabilities on the condensed consolidated balance sheets related to the Embolitech Transaction. As of September 30, 2019, $1.0 million and $2.1 million is included in other accrued liabilities and other long-term liabilities, respectively, on the consolidated balance sheets related to the Embolitech Transaction.

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (16,592)	$ (15,769)
Intangible assets, Gross Carrying Amount	30,377	29,995
Intangible assets, Net	$ 13,785	$ 14,226
Customer Lists and Relationships [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years 10 months 24 days	8 years 10 months 24 days
Definite-lived intangible assets, Gross Carrying Amount	$ 17,684	$ 17,374
Definite-lived intangible assets, Accumulated Amortization	(11,177)	(10,661)
Definite-lived intangible assets, Net	$ 6,507	$ 6,713
Developed Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	11 years 6 months	11 years 6 months
Definite-lived intangible assets, Gross Carrying Amount	$ 9,562	$ 9,490
Definite-lived intangible assets, Accumulated Amortization	(3,453)	(3,196)
Definite-lived intangible assets, Net	$ 6,109	$ 6,294
Non-compete [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	5 years	5 years
Definite-lived intangible assets, Gross Carrying Amount	$ 230	$ 230
Definite-lived intangible assets, Accumulated Amortization	(207)	(196)
Definite-lived intangible assets, Net	$ 23	$ 34
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	16 years 6 months	16 years 6 months
Definite-lived intangible assets, Gross Carrying Amount	$ 2,321	$ 2,321
Definite-lived intangible assets, Accumulated Amortization	(1,755)	(1,716)
Definite-lived intangible assets, Net	566	605
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	29,797	29,415
Definite-lived intangible assets, Accumulated Amortization	(16,592)	(15,769)
Definite-lived intangible assets, Net	13,205	13,646
Trademarks and Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 580	$ 580

Stock-based Compensation - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,393	$ 1,231
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	33	32
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	262	213
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,098	$ 986

Stock-based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2017	Sep. 30, 2019	Sep. 30, 2018
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs related to non-vested awards	$ 10,500,000
Weighted average period for recognition of compensation costs related to non-vested awards	2 years 8 months 12 days
Weighted average per share fair value of stock options	$ 14.38	$ 18.30
Dividend yield	0.00%	0.00%
Stock-based compensation	$ 1,393,000	$ 1,231,000
Total pre-tax intrinsic value of options exercised	$ 200,000	100,000
Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year	2017
Performance period end year	2019
Nonqualified Stock Options [Member]
Stock-Based Compensation Activity [Line Items]
Stock-based compensation	$ 600,000	500,000
Nonqualified Stock Options [Member] \| Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	4 years
Nonqualified Stock Options [Member] \| Minimum [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service	7 years
Nonqualified Stock Options [Member] \| Maximum [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	1 year
Restricted Stock Awards [Member]
Stock-Based Compensation Activity [Line Items]
Stock-based compensation	$ 500,000	$ 400,000
Number of stock units awarded	54,694	42,248
Number of stock units forfeited	4,099	507
Number of stock units outstanding	99,500			90,409
Restricted Stock Awards [Member] \| Minimum [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	1 year
Restricted Stock Awards [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	3 years
Performance Shares [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period			3 years
Stock-based compensation		$ 200,000
Issuance of common stock, shares	67,653
Issuance of common stock	$ 2,800,000
Performance Shares [Member] \| Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of stock units granted			$ 1,200,000
1999 Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Annual compensation withheld, maximum limit	25,000
1999 Employee Stock Purchase Plan [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Stock-based compensation	$ 100,000	100,000
Common stock authorized, shares	600,000
Annual compensation withheld	10.00%
Employee contributions	$ 100,000			$ 100,000
Restricted Stock Units (RSUs) [Member] \| 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock-based compensation	$ 200,000	$ 100,000
Number of stock units awarded	8,032	6,206
Number of stock units outstanding	62,113			62,242
Deferred Stock Units [Member] \| 2009 Equity Incentive Plan [Member] \| Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock-based compensation	$ 100,000	$ 100,000
Number of stock units awarded	823	751
Number of stock units outstanding	30,552				29,729
Deferred Stock Units [Member] \| Maximum [Member] \| 2009 Equity Incentive Plan [Member] \| Director [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of stock units granted	$ 100,000	$ 100,000
Vesting Anniversary [Member] \| Nonqualified Stock Options [Member] \| Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage	25.00%

Other Assets - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Schedule of Investments [Line Items]
Other assets	$ 4,125	$ 2,124
ViaCyte, Inc. [Member]
Schedule of Investments [Line Items]
Other assets	479	479
Operating Lease Right-of-Use Assets [Member]
Schedule of Investments [Line Items]
Other assets	1,696
Other Noncurrent Assets [Member]
Schedule of Investments [Line Items]
Other assets	$ 1,950	$ 1,645

Segment Information - Segment Revenue, Operating (Loss) Income and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue	$ 22,616	$ 22,241
Operating (loss) income	(266)	712
Depreciation and amortization	1,804	1,756
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	22,616	22,241
Operating (loss) income	2,176	2,812
Operating Segments [Member] \| Medical Device [Member]
Segment Reporting Information [Line Items]
Revenue	17,404	17,258
Operating (loss) income	(423)	357
Depreciation and amortization	1,455	1,388
Operating Segments [Member] \| In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	5,212	4,983
Operating (loss) income	2,599	2,455
Depreciation and amortization	110	116
Corporate [Member]
Segment Reporting Information [Line Items]
Operating (loss) income	(2,442)	(2,100)
Depreciation and amortization	$ 239	$ 252

Stock-based Compensation

3 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation

11. Stock-based Compensation

The Company has stock-based compensation plans under which it grants stock options, restricted stock awards, performance share awards, restricted stock units and deferred stock units. Accounting guidance requires all share-based payments to be recognized as an operating expense, based on their fair values, over the requisite service period.

The Company’s stock-based compensation expenses were allocated to the following expense categories:

	Three Months Ended
	December 31,
(Dollars in thousands)	2019		2018
Product costs	$	33	$	32
Research and development		262		213
Selling, general and administrative		1,098		986
Total	$	1,393	$	1,231

As of December 31, 2019, approximately $10.5 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.7 years.

Stock Option Awards

The Company uses the Black-Scholes option pricing model to determine the weighted average grant date fair value of stock options granted. The weighted average per share fair values of stock options granted during the three months ended December 31, 2019 and 2018 were $14.38 and $18.30, respectively.

	Three Months Ended
	December 31,
	2019			2018
Risk-free interest rates		1.6	%		2.9	%
Expected life (years)		4.6			4.5
Expected volatility		37.8	%		33.2	%
Dividend yield		0.0	%		0.0	%

The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the awards. The expected life of options granted was determined based on the Company’s experience. Expected volatility was based on the Company’s stock price movement over a period approximating the expected term. Based on management’s judgment, dividend yields were expected to be 0.0% for the expected life of the options. The Company also estimated forfeitures of options granted, which were based on historical experience.

Non-qualified stock options are granted at fair market value on the date of grant. Non-qualified stock options expire in seven years upon termination of employment or service as a Board member. With respect to members of our Board, non-qualified stock options generally become exercisable on a pro-rata basis within the one-year period following the date of grant. With respect to our employees, non-qualified stock options generally become exercisable with respect to 25% of the shares on each of the first four anniversaries following the grant date. The stock-based compensation table above includes stock option expenses recognized related to these awards, which totaled $0.6 million and $0.5 million for the three months ended December 31, 2019 and 2018.

The total pre-tax intrinsic value of options exercised during the three months ended December 31, 2019 and 2018 was $0.2 million and less than $0.1 million, respectively. The intrinsic value represents the difference between the Company’s common stock fair market value on the date of exercise and the option’s exercise price.

Restricted Stock Awards

The Company has entered into restricted stock agreements with certain key employees, covering the issuance of common stock (“Restricted Stock”). Under accounting guidance, these shares are considered to be non-vested shares. The Restricted Stock is released to the key employees if they are employed by the Company at the end of the vesting period. Restricted Stock vesting periods range from one to three years. During the three months ended December 31, 2019 and 2018, the Company awarded 54,694 and 42,248 Restricted Stock shares, respectively, to certain key employees and officers. Forfeiture of 4,099 and 507 Restricted Stock shares occurred during the three months ended December 31, 2019 and 2018, respectively. As of December 31, 2019 and September 30, 2019, 99,500 and 90,409 Restricted Stock shares were outstanding, respectively. Compensation expense has been recognized for the estimated fair value of the common shares, net of estimated forfeitures, and is being charged to operating expenses over the vesting term. The stock-based compensation expense table includes Restricted Stock expenses recognized related to these awards, which totaled $0.5 million and $0.4 million for the three months ended December 31, 2019 and 2018, respectively.

Performance Share Awards

The Company has entered into performance share agreements with certain key employees covering the issuance of common stock (“Performance Shares”). Performance Shares vest upon the achievement of all or a portion of certain performance objectives (which may include financial or project objectives), which must be achieved during the performance period. The Organization and Compensation Committee of the Board of Directors (the “Committee”) approves the performance objectives used for our executive compensation programs, which objectives were cumulative revenue and cumulative earnings before interest, income taxes, depreciation and amortization (“EBITDA”) for the three-year performance periods for awards granted in fiscal 2017 (2017 – 2019). The fiscal 2017 awards also included performance objectives related to achievement of the Company’s strategic initiatives. Awards granted in fiscal 2017 were finalized in the three months ended December 31, 2019 and resulted in the issuance of 67,653 shares, with a value of $2.8 million, based on the performance objectives relative to actual results achieved during the performance period. The per share compensation cost for each award was fixed on the grant date. The stock-based compensation expense table includes Performance Shares expense recognized related to these awards, which totaled $0.2 million for the three months ended December 31, 2018. Performance Shares expense recognized in the three months ended December 31, 2019 was insignificant as all Performances Shares were vested as of September 30, 2019.

The fair values of the Performance Shares, at target, were $1.2 million for awards granted in fiscal 2017. There have been no Performance Share awards granted subsequent to fiscal 2017.

1999 Employee Stock Purchase Plan

Under the amended 1999 Employee Stock Purchase Plan (“Stock Purchase Plan”), the Company is authorized to issue up to 600,000 shares of common stock. All full-time and part-time U.S. employees can choose to have up to 10% of their annual compensation withheld, with a limit of $25,000, to purchase the Company’s common stock at purchase prices defined within the provisions of the Stock Purchase Plan. As of December 31, 2019 and September 30, 2019, there was less than $0.1 million of employee contributions included in accrued liabilities in the condensed consolidated balance sheets. Stock compensation expense recognized related to the Stock Purchase Plan for the three months ended December 31, 2019 and 2018 totaled less than $0.1 million in each respective period. The stock-based compensation table includes the Stock Purchase Plan expenses.

Restricted Stock and Deferred Stock Units

During the three months ended December 31, 2019 and 2018, the Company awarded 8,032 and 6,206 restricted stock units (“RSUs”), respectively, to non-employee directors and certain key employees in foreign jurisdictions. RSU awards are not considered issued or outstanding common stock of the Company until they vest. As of December 31, 2019 and September 30, 2019, outstanding, unvested RSUs totaled 62,113 and 62,242, respectively. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to operating expenses over the vesting term. The estimated fair value of the RSUs was calculated based on the closing market price of Surmodics’ common stock on the grant date. The stock-based compensation table includes RSU expenses recognized related to these awards, which totaled $0.2 million and $0.1 million for the three months ended December 31, 2019 and 2018, respectively.

Directors may elect to receive their annual fees for services to the Board in deferred stock units (“DSUs”). Directors may elect this option quarterly. During the three months ended December 31, 2019 and 2018, 823 and 751 units, respectively, were issued with a total fair value of less than $0.1 million in each period. As of December 31, 2019 and September 30, 2018, outstanding, fully vested DSUs totaled 30,552 and 29,729, respectively. Stock-based compensation expense related to DSU awards totaled less than $0.1 million for both the three months ended December 31, 2019 and 2018.

Other Assets - Additional Information (Detail) - ViaCyte, Inc. [Member] $ in Millions	3 Months Ended
	Dec. 31, 2019 USD ($)
Schedule of Investments [Line Items]
Equity method investment	$ 5.3
Other than temporary impairment loss on investment	4.8
Cost method of investment	$ 0.5
Maximum [Member]
Schedule of Investments [Line Items]
Company's ownership percentage	1.00%

Inventories

3 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Inventories

6. Inventories

Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead, with cost of product sales determined on a first-in, first-out basis. Inventories consisted of the following components:

	December 31,		September 30,
(Dollars in thousands)	2019		2019
Raw materials	$	2,409	$	2,034
Work-in process		1,349		892
Finished products		1,193		1,575
Total	$	4,951	$	4,501

Segment Information

3 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Segment Information

14. Segment Information

The Company’s management evaluates performance and allocates resources based on reported results for two reportable segments, as follows: (1) the Medical Device unit, which designs, develops and manufactures interventional medical devices, primarily for the peripheral vascular market; surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices; as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.

Segment revenue, operating (loss) income, and depreciation and amortization, were as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2019			2018
Revenue:
Medical Device	$	17,404		$	17,258
In Vitro Diagnostics		5,212			4,983
Total revenue	$	22,616		$	22,241

Operating (loss) income:
Medical Device	$	(423	)	$	357
In Vitro Diagnostics		2,599			2,455
Total segment operating income		2,176			2,812
Corporate		(2,442	)		(2,100	)
Total operating (loss) income	$	(266	)	$	712

Depreciation and amortization:
Medical Device	$	1,455		$	1,388
In Vitro Diagnostics		110			116
Corporate		239			252
Total depreciation and amortization	$	1,804		$	1,756

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses which are not specific to a segment and thus not allocated to the operating segments.

Asset information by operating segment is not presented because the Company does not provide its chief operating decision maker assets by operating segment, as the data is not readily available or significant to the decision-making process.

Other Assets

3 Months Ended

Dec. 31, 2019

Investments All Other Investments [Abstract]

Other Assets

7. Other Assets

Other assets consisted of the following:

	December 31,		September 30,
(Dollars in thousands)	2019		2019
ViaCyte, Inc.	$	479	$	479
Operating lease right-of-use assets		1,696		—
Other noncurrent assets		1,950		1,645
Other assets	$	4,125	$	2,124

The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. The balance of the investment of $0.5 million, which is net of previously recorded other-than-temporary impairments of $4.8 million, is accounted for under the cost method and represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities.

The carrying value of each cost method investment is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investment.

Other noncurrent assets include prepaid expenses related to our ongoing clinical trials and a receivable related to refundable Irish research and development tax credits.

Accrued Liabilities - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 257	$ 434
Accrued clinical study expense	1,438	2,163
Accrued purchases	1,150	679
Acquisition of in process research and development	1,167	989
Current portion of lease liability	472
Deferred rent		130
Other	394	395
Total	$ 4,878	$ 4,790

Revenue - Additional Information (Detail) - Abbott [Member] - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01 $ in Millions	Dec. 31, 2019 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Estimated revenue to be recognized in future	$ 15.8
Expected period to recognize the remaining revenue	6 years

Net Income Per Share Data (Tables)

3 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Denominator for Computation of Basic and Diluted Net Income Per Share

The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands):

	Three Months Ended
	December 31,
	2019		2018
Net income available to common shareholders	$	148	$	1,310
Basic weighted average shares outstanding		13,469		13,367
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares		300		460
Diluted weighted average shares outstanding		13,769		13,827

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Payment for contingent consideration liability, operating activities	$ 608,000	$ 2,041,000
Payment for contingent consideration liability, financing activities	2,592,000	$ 9,064,000
Transfers in or out Level 3, Assets	0		$ 0
Transfers in or out Level 3, Liabilities	0		0
Transfers out of Level 1 to Level 2, Assets	0		0
Transfers into Level 1 out of Level 2, Assets	0		0
Transfers out of Level 1 to Level 2, Liabilities	0		0
Transfers into Level 1 out of Level 2, Liabilities	0		$ 0
NorMedix [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability	3,200,000
Payment for contingent consideration liability, operating activities	600,000
Payment for contingent consideration liability, financing activities	$ 2,600,000

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2019	Feb. 04, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	SRDX
Security Exchange Name	NASDAQ
Entity Registrant Name	SURMODICS INC
Entity Central Index Key	0000924717
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.05 par value
Entity File Number	0-23837
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-1356149
Entity Address, Address Line One	9924 West 74th Street
Entity Address, City or Town	Eden Prairie
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55344
City Area Code	952
Local Phone Number	500-7000
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		13,590,159

Goodwill (Tables)

3 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Carrying Amount of Goodwill By Segment

Changes in the carrying amount of goodwill by segment were as follows:

(Dollars in thousands)	In Vitro Diagnostics		Medical Device		Total
Balance as of September 30, 2019	$	8,010	$	18,161	$	26,171
Currency translation adjustment		—		375		375
Balance as of December 31, 2019	$	8,010	$	18,536	$	26,546

Income Taxes

3 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

13. Income Taxes

For interim income tax reporting, the Company estimates its annual effective tax rate and applies it to year-to-date pretax (loss) income, excluding unusual or infrequently occurring discrete items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company recorded income tax benefit of $0.3 million and $0.2 million for the three months ended December 31, 2019 and 2018, respectively.

The effective income tax rate for the three months ended December 31, 2019 and 2018 differs from the U.S. federal statutory tax rate of 21% primarily due to the favorable impacts of the U.S. federal research and development tax credits in both periods, as well as stock award activity in the three-month period and operating results of our Irish subsidiary, where tax benefit is offset by a valuation allowance. The effective income tax rate for the three months ended December 31, 2019 and 2018 was impacted by discrete tax benefits of $0.2 million and $0.5 million, respectively, related to share awards vested, expired, cancelled and exercised during the periods.

The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate is $2.7 million and $2.1 million as of December 31, 2019 and September 30, 2019, respectively. Interest and penalties related to unrecognized tax benefits are recorded in the income tax (benefit) provision.

The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. U.S. income tax returns for years prior to fiscal 2015 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2009. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2014. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical and NorMedix for periods prior to their respective acquisition dates, pursuant to the terms of the related share purchase agreements. As of December 31, 2019 and September 30, 2019, there were no undistributed earnings in foreign subsidiaries.

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 176	$ 200
Series A Preferred stock, par value	$ 0.05	$ 0.05
Series A Preferred stock, shares authorized	450,000	450,000
Series A Preferred stock, shares issued	0	0
Series A Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	13,593,069	13,504,102
Common stock, shares outstanding	13,593,069	13,504,102

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Activities:
Net income	$ 148	$ 1,310
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	1,804	1,756
Stock-based compensation	1,393	1,231
Payment of contingent consideration obligations in excess of acquisition-date value	(608)	(2,041)
Contingent consideration gain		(35)
Deferred taxes	(194)	310
Gain on strategic investment		(7)
Provision for bad debts	(27)	63
Other	50	12
Change in operating assets and liabilities:
Accounts receivable and contract asset	1,726	(762)
Inventories	(413)	(161)
Prepaids and other	(800)	(649)
Accounts payable	529	190
Accrued liabilities	(3,112)	(3,737)
Income taxes	(59)	(496)
Deferred revenue	(1,346)	(2,389)
Net cash used in operating activities	(909)	(5,405)
Investing Activities:
Purchases of property and equipment	(1,671)	(2,066)
Purchases of available-for-sale securities	(21,758)	(10,098)
Maturities of available-for-sale securities	7,425	20,000
Cash received from sale of strategic investment		7
Net cash (used in) provided by investing activities	(16,004)	7,843
Financing Activities:
Issuance of common stock	91	36
Payments for taxes related to net share settlement of equity awards	(1,964)	(2,661)
Payment of contingent consideration obligations	(2,592)	(9,064)
Net cash used in financing activities	(4,465)	(11,689)
Effect of exchange rate changes on cash and cash equivalents	23	(15)
Net change in cash and cash equivalents	(21,355)	(9,266)
Cash and Cash Equivalents:
Beginning of period	30,361	23,668
End of period	9,006	14,402
Supplemental Information:
Cash paid for income taxes	4	3
Noncash transactions from investing and financing activities:
Acquisition of property and equipment, net of refundable credits in other current assets and liabilities	$ 167	$ 147

Revenue - Summary of Revenues Disaggregated by Product Classification and Operating Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Total revenue	$ 22,616	$ 22,241
Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	9,974	9,751
Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	10,148	10,096
Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2,494	2,394
Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	22,616	22,241
Operating Segments [Member] \| Medical Device [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	17,404	17,258
Operating Segments [Member] \| Medical Device [Member] \| Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5,023	4,778
Operating Segments [Member] \| Medical Device [Member] \| Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	8,898	7,685
Operating Segments [Member] \| Medical Device [Member] \| Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2,234	2,384
Operating Segments [Member] \| Medical Device [Member] \| License Fees [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,249	2,411
Operating Segments [Member] \| In Vitro Diagnostics [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5,212	4,983
Operating Segments [Member] \| In Vitro Diagnostics [Member] \| Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	4,952	4,973
Operating Segments [Member] \| In Vitro Diagnostics [Member] \| Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 260	$ 10

Revenue (Tables)

3 Months Ended

Dec. 31, 2019

Revenue From Contract With Customer [Abstract]

Summary of Revenues Disaggregated by Product Classification and Operating Segment

The following table presents our revenues disaggregated by product classification and by operating segment, excluding sales taxes collected and remitted to governmental authorities (in thousands, unaudited).

	Three Months Ended
	December 31,
(Dollars in thousands)	2019		2018
Medical Device
Product sales	$	5,023	$	4,778
Royalties		8,898		7,685
Research, development and other		2,234		2,384
License fees		1,249		2,411
Total Revenue - Medical Device		17,404		17,258
IVD
Product sales		4,952		4,973
Other		260		10
Total Revenue - IVD		5,212		4,983
Total Revenue	$	22,616	$	22,241

Stock-based Compensation (Tables)

3 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expenses

The Company’s stock-based compensation expenses were allocated to the following expense categories:

	Three Months Ended
	December 31,
(Dollars in thousands)	2019		2018
Product costs	$	33	$	32
Research and development		262		213
Selling, general and administrative		1,098		986
Total	$	1,393	$	1,231

Assumptions Used in Stock Option Plans

	Three Months Ended
	December 31,
	2019			2018
Risk-free interest rates		1.6	%		2.9	%
Expected life (years)		4.6			4.5
Expected volatility		37.8	%		33.2	%
Dividend yield		0.0	%		0.0	%

Accrued Liabilities

3 Months Ended

Dec. 31, 2019

Payables And Accruals [Abstract]

Accrued Liabilities

10. Accrued Liabilities

Accrued liabilities consisted of the following:

	December 31,		September 30,
(Dollars in thousands)	2019		2019
Accrued professional fees	$	257	$	434
Accrued clinical study expense		1,438		2,163
Accrued purchases		1,150		679
Acquisition of in process research and development		1,167		989
Current portion of lease liability		472		—
Deferred rent		—		130
Other		394		395
Total	$	4,878	$	4,790

Fair Value Measurements (Tables)

3 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about the Company’s assets measured at fair value on a recurring basis as of December 31, 2019:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value as of December 31, 2019
Assets
Cash equivalents	$	—	$	6,286	$	—	$	6,286
Available-for-sale securities		—		39,256		—		39,256
Total assets	$	—	$	45,542	$	—	$	45,542

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2019:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of September 30, 2019
Assets
Cash equivalents	$	—	$	24,375	$	—		$	24,375
Available-for-sale securities		—		24,931		—		$	24,931
Total assets	$	—	$	49,306	$	—		$	49,306

Liabilities
Contingent consideration	$	—	$	—	$	(3,200	)	$	(3,200	)
Total liabilities	$	—	$	—	$	(3,200	)	$	(3,200	)

Schedule of Contingent Consideration Liabilities Measured at Fair Value

Changes in the contingent consideration liabilities measured at fair value using Level 3 inputs were as follows : three months ended December 31, 2019 and 2018

	Three Months Ended
	December 31,
(Dollars in thousands)	2019			2018
Beginning balance	$	3,200		$	14,466
Additions		—			—
Fair value adjustments		—			(149	)
Settlements		(3,200	)		(10,979	)
Interest accretion		—			114
Foreign currency translation loss (gain)		—			(126	)
Ending balance	$	—		$	3,326

Goodwill

3 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill

9. Goodwill

Goodwill represents the excess of the cost of an acquired entity over the fair value assigned to the assets purchased and liabilities assumed in connection with a business acquisition. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that the carrying amount of goodwill may be impaired.

Goodwill as of December 31, 2019 and September 30, 2019 totaled $26.5 million and $26.2 million, respectively. Goodwill in the Medical Device reporting unit represents the gross value from the fiscal 2016 acquisitions of Creagh Medical Limited (“Creagh Medical”) and NorMedix. Goodwill in the In Vitro Diagnostics reporting unit represents the gross value from the acquisition of BioFX Laboratories, Inc. (“BioFX”) in fiscal 2007.

Goodwill was not impaired in either reporting unit based on the outcome of the fiscal 2019 annual impairment test, and there have been no events or circumstances that have occurred in the first three months of fiscal 2020 to indicate that goodwill has been impaired.

Changes in the carrying amount of goodwill by segment were as follows:

(Dollars in thousands)	In Vitro Diagnostics		Medical Device		Total
Balance as of September 30, 2019	$	8,010	$	18,161	$	26,171
Currency translation adjustment		—		375		375
Balance as of December 31, 2019	$	8,010	$	18,536	$	26,546

Leases

3 Months Ended

Dec. 31, 2019

Leases [Abstract]

Leases

15. Leases

The Company leases facilities for research, office, manufacturing and warehousing. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability based on the net present value of the future minimum lease payments over the lease term at the commencement date. The unamortized balance of leasehold improvement incentives in the form of tenant allowances represents the primary difference between the balance of the right-of-use assets and operating lease liabilities. As the Company’s leases typically do not provide an implicit rate, the Company’s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. The condensed consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the condensed consolidated statements of income on a straight-line basis over the lease term.

The Company’s leases include one or more options to renew and extend the lease term at the Company’s discretion. These renewal options are not included in our right-of-use assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal period in our lease term.

The Company's operating lease cost for the three months ended December 31, 2019 was $0.1 million. Cash paid for operating lease liabilities approximated operating lease cost for the three months ended December 31, 2019.

Operating lease right-of-use assets and operating lease liabilities were as follows:

	December 31,
(Dollars in thousands)	2019
Right-of-use assets
Other assets	$	1,696

Operating lease liabilities:
Other accrued liabilities	$	472
Other long-term liabilities		2,394
Total operating lease liabilities	$	2,866

As of December 31, 2019, operating lease maturities for the remainder of fiscal 2020 and each of the next five fiscal years are as follows (in thousands):

Remainder of 2020	$	376
2021		538
2022		536
2023		547
2024		558
2025		570
Thereafter		1,965
Total expected operating lease payments		5,090
Less: Imputed interest		(2,224	)
Total operating lease liabilities	$	2,866

As of December 31, 2019, the weighted average remaining lease term for operating leases was 8.2 years and the weighted average discount rate used to determine operating lease liabilities was 4.6%.

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue:
Total revenue	$ 22,616	$ 22,241
Operating costs and expenses:
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Product costs	$ 3,203	$ 3,523
Research and development	12,142	11,486
Selling, general and administrative	6,943	5,949
Acquired intangible asset amortization	594	606
Contingent consideration gain		(35)
Total operating costs and expenses	22,882	21,529
Operating (loss) income	(266)	712
Other income:
Investment income, net	250	316
Interest expense	(40)	(37)
Foreign exchange (loss) gain	(47)	136
Other	1	7
Other income	164	422
(Loss) income before income taxes	(102)	1,134
Income tax benefit	250	176
Net income	$ 148	$ 1,310
Basic net income per share:	$ 0.01	$ 0.10
Diluted net income per share:	$ 0.01	$ 0.09
Weighted average number of shares outstanding:
Basic	13,469	13,367
Diluted	13,769	13,827
Product Sales [Member]
Revenue:
Total revenue	$ 9,974	$ 9,751
Royalties and License Fees [Member]
Revenue:
Total revenue	10,148	10,096
Research, Development and Other [Member]
Revenue:
Total revenue	$ 2,494	$ 2,394

Net Income Per Share Data - Additional Information (Detail) - USD ($) shares in Millions	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Nov. 05, 2014
Earnings Loss Per Share [Line Items]
Anti-dilutive outstanding stock options	0.1	0.1
Accelerated Share Repurchase Program [Member]
Earnings Loss Per Share [Line Items]
Maximum payments for repurchase of common stock			$ 25,300,000

Net Income Per Share Data

3 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Net Income Per Share Data

12. Net Income Per Share Data

Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options, non-vested stock relating to restricted stock awards, restricted stock units and deferred stock units, as well as performance shares in years prior to fiscal 2020. Options to purchase shares of common stock as well as unvested restricted stock and performance stock units are considered to be potentially dilutive common shares.

The calculation of weighted average diluted shares outstanding excludes outstanding stock options associated with the right to purchase 0.1 million shares of common stock for both the three months ended December 31, 2019 and 2018, as their inclusion would have had an antidilutive effect on diluted net income per share for those periods.

The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands):

	Three Months Ended
	December 31,
	2019		2018
Net income available to common shareholders	$	148	$	1,310
Basic weighted average shares outstanding		13,469		13,367
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares		300		460
Diluted weighted average shares outstanding		13,769		13,827

The Company’s Board of Directors has authorized the repurchase of up to $25.3 million of the Company’s outstanding common stock. This authorization does not have an expiration date.

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income tax benefit	$ 250,000	$ 176,000
U.S. federal statutory tax rate	21.00%	21.00%
Discrete tax benefit	$ 200,000	$ 500,000
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate	2,700,000		$ 2,100,000
Undistributed earnings in foreign subsidiaries	$ 0		$ 0

Inventories (Tables)

3 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Components of Inventories

Inventories consisted of the following components:

	December 31,		September 30,
(Dollars in thousands)	2019		2019
Raw materials	$	2,409	$	2,034
Work-in process		1,349		892
Finished products		1,193		1,575
Total	$	4,951	$	4,501

Revenue

3 Months Ended

Dec. 31, 2019

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

	Three Months Ended
	December 31,
(Dollars in thousands)	2019		2018
Medical Device
Product sales	$	5,023	$	4,778
Royalties		8,898		7,685
Research, development and other		2,234		2,384
License fees		1,249		2,411
Total Revenue - Medical Device		17,404		17,258
IVD
Product sales		4,952		4,973
Other		260		10
Total Revenue - IVD		5,212		4,983
Total Revenue	$	22,616	$	22,241

Contract Assets, Deferred Revenue and Remaining Performance Obligations

Contract asset balances consist of estimated sales-based royalties earned but not collected at each balance sheet date and are subject to timing fluctuations at the end of a given period. The Company’s deferred revenue, or contract liability, is primarily related to the upfront and milestone payments received pursuant to the collaborative license and commercialization agreement with Abbott (the “Abbott Agreement”) for the Company’s SurVeil™ drug-coated balloon product (“SurVeil DCB”) discussed in Note 3.

As of December 31, 2019, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more totaled approximately $15.8 million. These remaining performance obligations relate to the Abbott Agreement (Note 3), exclude contingent milestone payments under the Abbott Agreement, and are expected to be recognized over the next six years as services, principally the TRANSCEND study, are completed.

Fair Value Measurements

3 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

The accounting guidance on fair value measurements defines fair value, establishes a framework for measuring fair value under GAAP, and expands disclosures about fair value measurements. The guidance is applicable for all financial assets and financial liabilities and for all nonfinancial assets and nonfinancial liabilities recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.

Fair Value Hierarchy

Accounting guidance on fair value measurements requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities.

The Company did not have any Level 1 assets as of December 31, 2019 and September 30, 2019.

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.

The Company’s Level 2 assets as of December 31, 2019 and September 30, 2019 consisted of money market funds, commercial paper instruments and corporate bonds.

Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.

The Level 3 liability as of September 30, 2019 consisted of contingent consideration obligations related to the fiscal 2016 acquisition of NorMedix, Inc. (“NorMedix”). Consideration owed to the sellers of NorMedix from revenue and value-creating milestones achieved through September 30, 2019 totaling $3.2 million was paid during the three months ended December 31, 2019, with $0.6 million and $2.6 million classified as cash flows used in operating and financing activities, respectively, on the condensed consolidated statements of cash flows.

In valuing Level 3 assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

The following table presents information about the Company’s assets measured at fair value on a recurring basis as of December 31, 2019:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value as of December 31, 2019
Assets
Cash equivalents	$	—	$	6,286	$	—	$	6,286
Available-for-sale securities		—		39,256		—		39,256
Total assets	$	—	$	45,542	$	—	$	45,542

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2019:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of September 30, 2019
Assets
Cash equivalents	$	—	$	24,375	$	—		$	24,375
Available-for-sale securities		—		24,931		—		$	24,931
Total assets	$	—	$	49,306	$	—		$	49,306

Liabilities
Contingent consideration	$	—	$	—	$	(3,200	)	$	(3,200	)
Total liabilities	$	—	$	—	$	(3,200	)	$	(3,200	)

Changes in the contingent consideration liabilities measured at fair value using Level 3 inputs were as follows : three months ended December 31, 2019 and 2018

	Three Months Ended
	December 31,
(Dollars in thousands)	2019			2018
Beginning balance	$	3,200		$	14,466
Additions		—			—
Fair value adjustments		—			(149	)
Settlements		(3,200	)		(10,979	)
Interest accretion		—			114
Foreign currency translation loss (gain)		—			(126	)
Ending balance	$	—		$	3,326

There were no transfers of assets or liabilities between amounts measured using Level 1, Level 2, or Level 3 fair value measurements in fiscal 2020 and fiscal 2019.

Valuation Techniques

The valuation techniques used to measure the fair value of assets are as follows:

Cash equivalents — These assets are classified as Level 2 and are carried at historical cost which is a reasonable estimate of fair value because of the relatively short time between origination of the instrument and its expected realization.

Available-for-sale securities — Fair market values for these assets are based on quoted vendor prices and broker pricing in active markets underlying the securities where all significant inputs are observable. To ensure the accuracy of quoted vendor prices and broker pricing, the Company performs regular reviews of investment returns to industry benchmarks and sample tests of individual securities to validate quoted vendor prices with other available market data.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Net Income Per Share Data - Denominator for Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Net income available to common shareholders	$ 148	$ 1,310
Basic weighted average shares outstanding	13,469	13,367
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares	300	460
Diluted weighted average shares outstanding	13,769	13,827

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 2,409	$ 2,034
Work-in process	1,349	892
Finished products	1,193	1,575
Total	$ 4,951	$ 4,501

Other Assets (Tables)

3 Months Ended

Dec. 31, 2019

Investments All Other Investments [Abstract]

Summary of Other Assets

Other assets consisted of the following:

	December 31,		September 30,
(Dollars in thousands)	2019		2019
ViaCyte, Inc.	$	479	$	479
Operating lease right-of-use assets		1,696		—
Other noncurrent assets		1,950		1,645
Other assets	$	4,125	$	2,124

Stock-based Compensation - Assumptions Used in Stock Option Plans (Detail)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rates	1.60%	2.90%
Expected life (years)	4 years 7 months 6 days	4 years 6 months
Expected volatility	37.80%	33.20%
Dividend yield	0.00%	0.00%

Investments (Tables)

3 Months Ended

Dec. 31, 2019

Investments Debt And Equity Securities [Abstract]

Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	December 31, 2019
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper and corporate bonds	$	39,251	$	5	$	—	$	39,256
Total	$	39,251	$	5	$	—	$	39,256

	September 30, 2019
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper and corporate bonds	$	24,918	$	13	$	—	$	24,931
Total	$	24,918	$	13	$	—	$	24,931

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]
Beginning balance at Sep. 30, 2018	$ 108,610	$ 670	$ 7,607	$ 2,718	$ 97,615
Beginning balance, shares at Sep. 30, 2018		13,398
Net impact from adoption of ASC Topic 606	5,498				5,498
Net income	1,310				1,310
Other comprehensive income (loss), net of tax	(534)			(534)
Issuance of common stock		$ 6	(6)
Issuance of common stock, shares		128
Common stock options exercised, net	36		36
Common stock options exercised, net, shares		1
Purchase of common stock to pay employee taxes	(2,530)	$ (2)	(2,528)
Purchase of common stock to pay employee taxes, shares		(44)
Stock-based compensation	1,231		1,231
Ending balance at Dec. 31, 2018	113,621	$ 674	6,340	2,184	104,423
Ending balance, shares at Dec. 31, 2018		13,483
Beginning balance at Sep. 30, 2019	122,516	$ 675	10,740	396	110,705
Beginning balance, shares at Sep. 30, 2019		13,504
Net income	148				148
Other comprehensive income (loss), net of tax	1,036			1,036
Issuance of common stock		$ 7	(7)
Issuance of common stock, shares		125
Common stock options exercised, net	91		91
Common stock options exercised, net, shares		8
Purchase of common stock to pay employee taxes	(1,858)	$ (2)	(1,856)
Purchase of common stock to pay employee taxes, shares		(44)
Stock-based compensation	1,393		1,393
Ending balance at Dec. 31, 2019	$ 123,326	$ 680	$ 10,361	$ 1,432	$ 110,853
Ending balance, shares at Dec. 31, 2019		13,593

Collaborative Arrangement - Additional Information (Detail) - Abbott [Member] - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fee received	$ 25,000,000
Collaborative arrangement milestone payment received	10,000,000
Collaboration revenue recognized	1,300,000	$ 2,400,000
Upfront and milestone fee payment included in deferred revenue	15,800,000		$ 17,100,000
Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement additional potential milestone payments receivable	$ 56,000,000

Accrued Liabilities (Tables)

3 Months Ended

Dec. 31, 2019

Payables And Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following:

	December 31,		September 30,
(Dollars in thousands)	2019		2019
Accrued professional fees	$	257	$	434
Accrued clinical study expense		1,438		2,163
Accrued purchases		1,150		679
Acquisition of in process research and development		1,167		989
Current portion of lease liability		472		—
Deferred rent		—		130
Other		394		395
Total	$	4,878	$	4,790

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 45,542	$ 49,306
Liabilities measured at fair value		(3,200)
Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	39,256	24,931
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	6,286	24,375
Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value		(3,200)
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	45,542	49,306
Significant Other Observable Inputs (Level 2) [Member] \| Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	39,256	24,931
Significant Other Observable Inputs (Level 2) [Member] \| Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 6,286	24,375
Level 3 Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value		(3,200)
Level 3 Liabilities [Member] \| Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value		$ (3,200)

Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Oct. 01, 2019
Right-of-use assets
Other assets	$ 1,696	$ 1,700
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent
Operating lease liabilities:
Other accrued liabilities	$ 472
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherAccruedLiabilitiesCurrent
Other long-term liabilities	$ 2,394
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesNoncurrent
Total operating lease liabilities	$ 2,866	$ 2,900

Leases (Tables)

3 Months Ended

Dec. 31, 2019

Leases [Abstract]

Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities

Operating lease right-of-use assets and operating lease liabilities were as follows:

	December 31,
(Dollars in thousands)	2019
Right-of-use assets
Other assets	$	1,696

Operating lease liabilities:
Other accrued liabilities	$	472
Other long-term liabilities		2,394
Total operating lease liabilities	$	2,866

Schedule of Operating Lease Maturities

As of December 31, 2019, operating lease maturities for the remainder of fiscal 2020 and each of the next five fiscal years are as follows (in thousands):

Remainder of 2020	$	376
2021		538
2022		536
2023		547
2024		558
2025		570
Thereafter		1,965
Total expected operating lease payments		5,090
Less: Imputed interest		(2,224	)
Total operating lease liabilities	$	2,866

Intangible Assets - Estimated Amortization Expense (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2020	$ 1,799
2021	2,319
2022	2,279
2023	1,668
2024	1,610
2025	$ 1,553

Segment Information - Additional Information (Detail)	3 Months Ended
Segment Information - Additional Information (Detail)	Dec. 31, 2019 Segment
Segment Reporting [Abstract]
Number of operating segments	2

Collaborative Arrangement

3 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaborative Arrangement

3. Collaborative Arrangement

Under the Abbott Agreement, Abbott will have exclusive worldwide commercialization rights for the SurVeil DCB to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial. Separately, Abbott also received options to negotiate agreements for Surmodics' below-the-knee and arteriovenous (“AV”) fistula DCB products, which are currently in pre-clinical development and a first-in human clinical study, respectively. Surmodics is responsible for conducting all necessary clinical trials and other activities required to achieve U.S. and European Union regulatory clearances for the SurVeil DCB, including completion of the ongoing TRANSCEND clinical trial. Abbott and Surmodics participate on a joint development committee charged with providing guidance on the Company’s clinical and regulatory activities with regard to the SurVeil product.

To account for the Abbott Agreement, the Company applied the guidance in ASC Topic 808 (Collaborative Arrangements) as the parties are active participants and are exposed to significant risks and rewards dependent on commercial success of the collaborative activity.

The Company has received a $25 million upfront fee as well as a $10 million milestone under the Abbott Agreement and may receive up to $56 million of additional payments upon achievement of various clinical and regulatory milestones. For the three months ended December 2019 and 2018, the Company recognized revenue totaling $1.3 million and $2.4 million, respectively, from the Abbott arrangement, all of which was previously included in deferred revenue. As of December 31, 2019 and September 30, 2019, deferred revenue from the upfront and milestone payments received of $15.8 million and $17.1 million, respectively, is recorded in the condensed consolidated balance sheets. Upon the commercialization of the SurVeil DCB, Surmodics will be responsible for the manufacture and supply of clinical and commercial quantities of the product. Revenue from these product sales, including a per-unit transfer price and a share of net profits resulting from third-party sales by Abbott, will be recognized if and when these products are shipped and control is transferred to the customer.

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Oct. 01, 2019
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Operating lease right-of-use assets	$ 1,696	$ 1,700
Operating lease liabilities	$ 2,866	2,900
Deferred rent liabilities		$ 1,200

Leases - Additional Information (Detail) $ in Millions	3 Months Ended
Leases - Additional Information (Detail) $ in Millions	Dec. 31, 2019 USD ($)
Leases [Abstract]
Lease description	The Company leases facilities for research, office, manufacturing and warehousing.
Lease, existence of option to extend	true
Lease, option to extend	The Company’s leases include one or more options to renew and extend the lease term at the Company’s discretion. These renewal options are not included in our right-of-use assets and lease liabilities as they are not reasonably certain of exercise.
Operating lease cost	$ 0.1
Weighted average remaining lease term for operating leases	8 years 2 months 12 days
Weighted average discount rate used to determine operating lease liabilities	4.60%

Intangible Assets (Tables)

3 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following:

	December 31, 2019
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,684	$	(11,177	)	$	6,507
Developed technology		11.5	$	9,562	$	(3,453	)	$	6,109
Non-compete		5.0	$	230	$	(207	)	$	23
Patents and other		16.5	$	2,321	$	(1,755	)	$	566
Subtotal				29,797		(16,592	)		13,205
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total			$	30,377	$	(16,592	)	$	13,785

	September 30, 2019
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,374	$	(10,661	)	$	6,713
Developed technology		11.5		9,490		(3,196	)		6,294
Non-compete		5.0		230		(196	)		34
Patents and other		16.5		2,321		(1,716	)		605
Subtotal				29,415		(15,769	)		13,646
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total			$	29,995	$	(15,769	)	$	14,226

Estimated Amortization Expense

Based on the intangible assets in service as of December 31, 2019, estimated amortization expense for the remainder of fiscal 2020 and each of the next five fiscal years is as follows (in thousands):

Remainder of 2020	$	1,799
2021		2,319
2022		2,279
2023		1,668
2024		1,610
2025		1,553

Investments

3 Months Ended

Dec. 31, 2019

Investments Debt And Equity Securities [Abstract]

Investments

5. Investments

Investments consisted principally of commercial paper and corporate bond securities and are classified as available-for-sale as of December 31, 2019 and September 30, 2019. These available-for-sale securities are reported at fair value with unrealized gains and losses, net of tax, excluded from the condensed consolidated statements of operations and reported in the condensed consolidated statements of comprehensive income as well as a separate component of stockholders’ equity in the condensed consolidated balance sheets, except for other-than-temporary impairments, which are reported as a charge to current earnings as they occur. A loss would be recognized when there is an other-than-temporary impairment in the fair value of any individual security classified as available-for-sale, with the associated net unrealized loss reclassified out of accumulated other comprehensive income with a corresponding adjustment to other income. This adjustment would result in a new cost basis for the investment. Interest earned on debt securities, including amortization of premiums and accretion of discounts, is included in investment income, net within other income. Realized gains and losses from the sales of debt securities, which are included in other income, are determined using the specific identification method. Investment purchases are accounted for on the date the trade is executed, which may not be the same as the date the transaction is cash settled.

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	December 31, 2019
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper and corporate bonds	$	39,251	$	5	$	—	$	39,256
Total	$	39,251	$	5	$	—	$	39,256

	September 30, 2019
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper and corporate bonds	$	24,918	$	13	$	—	$	24,931
Total	$	24,918	$	13	$	—	$	24,931

Fair Value Measurements - Schedule of Contingent Consideration Liabilities Measured at Fair Value (Detail) - Contingent Consideration [Member] - Significant Unobservable Inputs (Level 3) [Member] - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 3,200	$ 14,466
Fair value adjustments		(149)
Settlements	$ (3,200)	(10,979)
Interest accretion		114
Foreign currency translation loss (gain)		(126)
Ending balance		$ 3,326